Hepatitis C: how has France limited the expenses related to new treatments?-Reference-Cited by-同舟云学术

Hepatitis C: how has France limited the expenses related to new treatments?

Published:2016-10-27 Issue:6 Volume:16 Page:655-657
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Mouterde Anne-Laure¹,Bocquet François¹²³,Fusier Isabelle¹,Paubel Pascal¹²³

Affiliation:

1. Evaluation and Proper Use of Health Products, General Agency of Equipment and Health Products, Assistance Publique-Hôpitaux de Paris (AP-HP) 7 rue du Fer à Moulin, 75005 Paris, France

2. Health Law and Health Economics Departement, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, 4 avenue de l'Obervatoire, 75006 Paris, France

3. Health Law Institute, Inserm, UMR S 1145, Paris Descartes University, Sorbonne Paris Cité. 45 rue des Saints-Pères, 75006 Paris, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2016.1247696

Reference8 articles.

1. Effectiveness, costs weigh on HCV treatment decisions

2. Only just the beginning of the end of hepatitis C

3. New Expensive Treatments for Hepatitis C Infection

4. Inspection Générale des Affaires Sociales (IGAS). Evaluation médico-économique en santé, 2014 Dec. [in French]. [cited 2015 Oct 07]. Available from; http://www.ladocumentationfrancaise.fr/var/storage/rapports-publics/154000078.pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal intertemporal curative drug expenses: The case of hepatitis C in France;Journal of Health Economics;2024-03

2. Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib;Journal of Pharmaceutical Policy and Practice;2020-01-14

3. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat;Journal of Hepatology;2018-11

4. Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015;BMC Infectious Diseases;2017-12